Gilead Sciences (NASDAQ:GILD) Given New $102.00 Price Target at BMO Capital Markets

Gilead Sciences (NASDAQ:GILD) had its price target raised by BMO Capital Markets from $94.00 to $102.00 in a report published on Thursday morning,Benzinga reports. BMO Capital Markets currently has an outperform rating on the biopharmaceutical company’s stock.

GILD has been the subject of a number of other reports. Truist Financial upped their price target on Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. Leerink Partnrs raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Thursday. Sanford C. Bernstein began coverage on shares of Gilead Sciences in a research report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price objective for the company. Finally, JPMorgan Chase & Co. lifted their target price on Gilead Sciences from $95.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 9th. Twelve analysts have rated the stock with a hold rating, ten have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $90.71.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD traded down $1.34 during trading hours on Thursday, hitting $96.57. 7,456,749 shares of the stock were exchanged, compared to its average volume of 7,048,514. The firm has a market capitalization of $120.22 billion, a P/E ratio of 117.76, a P/E/G ratio of 3.13 and a beta of 0.17. Gilead Sciences has a one year low of $62.07 and a one year high of $98.32. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95. The company’s 50 day moving average is $85.30 and its 200 day moving average is $75.03.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The firm’s revenue was up 7.0% compared to the same quarter last year. During the same period last year, the business posted $2.29 earnings per share. On average, research analysts expect that Gilead Sciences will post 3.75 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 3.19%. The ex-dividend date is Friday, December 13th. Gilead Sciences’s dividend payout ratio is currently 375.61%.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 29,357 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the sale, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the sale, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now owns 78,127 shares in the company, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 62,437 shares of company stock worth $5,374,825. 0.29% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Gilead Sciences

A number of institutional investors and hedge funds have recently modified their holdings of GILD. Manning & Napier Advisors LLC acquired a new stake in Gilead Sciences in the 2nd quarter valued at approximately $25,328,000. Legal & General Group Plc increased its holdings in Gilead Sciences by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock valued at $851,743,000 after buying an additional 93,068 shares during the period. IRON Financial LLC bought a new position in Gilead Sciences in the third quarter valued at about $830,000. GSA Capital Partners LLP acquired a new stake in Gilead Sciences in the first quarter valued at approximately $462,000. Finally, Wealth Enhancement Advisory Services LLC grew its position in Gilead Sciences by 13.1% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock worth $19,630,000 after acquiring an additional 33,162 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.